ClearPoint Neuro, Inc. (CLPT)
- Previous Close
10.95 - Open
12.00 - Bid 11.47 x 200
- Ask 11.83 x 200
- Day's Range
11.40 - 12.82 - 52 Week Range
4.93 - 14.13 - Volume
203,676 - Avg. Volume
213,959 - Market Cap (intraday)
319.983M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.69 - Earnings Date Jan 6, 2025 - Jan 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.33
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
www.clearpointneuro.comRecent News: CLPT
View MorePerformance Overview: CLPT
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLPT
View MoreValuation Measures
Market Cap
301.78M
Enterprise Value
283.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.45
Price/Book (mrq)
10.41
Enterprise Value/Revenue
9.33
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-59.64%
Return on Assets (ttm)
-28.04%
Return on Equity (ttm)
-68.36%
Revenue (ttm)
30.43M
Net Income Avi to Common (ttm)
-18.15M
Diluted EPS (ttm)
-0.69
Balance Sheet and Cash Flow
Total Cash (mrq)
21.57M
Total Debt/Equity (mrq)
12.74%
Levered Free Cash Flow (ttm)
-1.29M
Research Analysis: CLPT
View MoreCompany Insights: CLPT
CLPT does not have Company Insights